Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans

Journal of Human Hypertension

Volumn 23, Issue 6, 2009, Pages 407-414

  Sarna, M A ^a   Hollenberg, N K ^b   Seely, E W ^b   Ahmed, S B ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Alberta Kidney Disease Network   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ALDOSTERONE; ANGIOTENSIN; CAPTOPRIL; DESOGESTREL; DIPEPTIDYL CARBOXYPEPTIDASE; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTAGEN; INSULIN; LEVONORGESTREL; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; RENIN; SODIUM;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; ENZYME INHIBITION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY CIRCULATION; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; SODIUM BALANCE; VASODILATATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; CAPTOPRIL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES MELLITUS, TYPE 1; ETHINYL ESTRADIOL; FEMALE; HUMANS; P-AMINOHIPPURIC ACID; PROGESTERONE CONGENERS; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY; YOUNG ADULT;

EID: 67349267352     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.148     Document Type: Article

References (61)

1. Hollenberg NK, Williams GH, Burger B, Chenitz W, Hoosmand I, Adams DF. Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake, and the renin-angiotensin system in healthy young women. Circ Res 1976; 38: 35-40.
2. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW et al Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol Regul Integr Comp Physiol 2001; 280: R807-R813.
3. Ahmed SB, Kang AK, Burns KD, Kennedy CR, Lai V, Cattran DC et al. Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. J Am Soc Nephrol 2004; 15 780-786.
4. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161: 2000-2005.
5. Ribstein J, Halimi JM, du Cailar G, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999; 33: 90-95.
6. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al Oral contraceptives, angiotens-independent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28: 1988-1994.
7. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277-283.
8. Fortepiani LA, Yanes L, Zhang H, Racusen LC, Reckelhoff JF. Role of androgens in mediating renal injury in aging SHR. Hypertension 2003; 42: 952-955.
9. Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP. Testosterone supplementation in aging men and women: Possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 2005; 289: F941-F948.
10. Szmuilowicz ED, Adler GK, Ricchiuti V, Hopkins PN, Seely EW. Relationships between endogenous sex hormone concentrations and vascular function in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 4738-4741.
11. Sitruk-Ware RL. Hormone therapy and the cardiovascular system: The critical role of progestins. Climacteric 2003; 6(Suppl 3): 21-28.
12. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645-650.
13. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-1793.
14. Singh M. Progestins and neuroprotection: Are all progestins created equal? Minerva Endocrinol 2007; 32: 95-102.
15. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
16. Arias-Loza PA, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J et al. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension 2006; 48: 994-1001.
17. Atthobari J, Gansevoort RT, Visser ST, de Jong PE, de Jong-van den Berg LT. The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate. Br J Clin Pharmacol 2007; 63: 224-231.
18. Hettiaratchi ES, Pickford M. The effect of oestrogen and progesterone on the pressor action of angiotensin in the rat. J Physiol 1968; 196: 447-451.
19. Nakamura T, Matsui K, Ito M, Yoshimura T, Kawasaki N, Fujisaki S et al. Effects of pregnancy and hormone treatments on pressor response to angiotensin II in conscious rats. Am J Obstet Gynecol 1988; 159: 989-995.
20. Greer JB, Modugno F, Allen GO, Ness RB. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol 2005; 105: 731-740.
21. Shoback DM,Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J Clin Endocrinol Metab 1983; 57: 764-770.
22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
23. Parving HH, Hommel E, Jensen BR, Hansen HP. Longterm beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228-234.
24. Osei SY, Price DA, Fisher ND, Porter L, Laffel LM, Hollenberg NK. Hyperglycemia and angiotensinmediated control of the renal circulation in healthy humans. Hypertension 1999; 33: 559-564.
25. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000; 36: 122-126.
26. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999; 10 1778-1785.
27. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
28. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005; 46: 1316-1320.
29. Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663-1672.
30. Pasinetti E, Falsetti L. Triphasic pills: Variability of endocrine parameters and of sex steroid-binding globulins. Acta Eur Fertil 1993; 24: 67-70.
31. Ellis J. Low-dose oral contraceptives: Progestin potency, androgenicity, and atherogenic potential. Clin Ther 1986; 8: 607-618.
32. Darney PD. The androgenicity of progestins. Am J Med 1995; 98 104S-110S.
33. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41: 345-352.
34. Madauss KP, Stewart EL,Williams SP. The evolution of progesterone receptor ligands. Med Res Rev 2007; 27: 374-400.
35. Winneker RC, Fensome A, Zhang P, Yudt MR, McComas CC, Unwalla RJ. A new generation of progesterone receptor modulators. Steroids 2008; 73: 689-701.
36. Lemale J, Bloch-Faure M, Grimont A, El Abida B, Imbert-Teboul M, Crambert G. Membrane progestin receptors alpha and gamma in renal epithelium. Biochim Biophys Acta 2008; 1783: 2234-2240.
37. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 1993; 41 671-678.
38. Boulkroun S, Le Moellic C, Blot-Chabaud M, Farman N, Courtois-Coutry N. Expression of androgen receptor and androgen regulation of NDRG2 in the rat renal collecting duct. Pflugers Arch 2005; 451: 388-394.
39. Winer BM. Renin in pregnancy and the menstrual cycle. J Clin Invest 1965; 44: 1112.
40. Chesley LC, Tepper IH. Effects of progesterone and estrogen on the sensitivity to angiotensin II. J Clin Endocrinol Metab 1967; 27 576-581.
41. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33: 1190-1194.
42. Oelkers WH. Drospirenone in combination with estrogens: For contraception and hormone replacement therapy. Climacteric 2005; 8(Suppl 3): 19-27.
43. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 2005; 45: 170-174.
44. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest 1989; 83: 1941-1945.
45. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19: 456-463.
46. Reckelhoff JF, Zhang H, Granger JP. Decline in renal hemodynamic function in aging SHR: Role of androgens. Hypertension 1997; 30 677-681.
47. Reckelhoff JF, Granger JP. Role of androgens in mediating hypertension and renal injury. Clin Exp Pharmacol Physiol 1999; 26: 127-131.
48. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: Role of the reninangiotensin system. Hypertension 2000; 35: 480-4
49. Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: A simple way to evaluate renin responsiveness. Ann Intern Med 1976; 84: 639-645.
50. James GD, Sealey JE, Muller F, Alderman M, Madhavan S, Laragh JH. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl 1986; 4: S387-S389.
51. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999; 55: 278-285.
52. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR et al Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol 2006; 17: 2554-2560.
53. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199-1208.
54. Gordon MS, Chin WW, Shupnik MA. Regulation of angiotensinogen gene expression by estrogen. J Hypertens 1992; 10: 361-366.
55. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J et al. Biological effects of estradiol-17 beta in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541.
56. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
57. Lansang MC, Price DA, Laffel LM, Osei SY, Fisher ND, Erani D et al Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59: 1432-1438.
58. Stanczyk FZ. All progestins are not created equal. Steroids 2003; 68: 879-890.
59. Cherney DZ, Scholey JW, Cattran DC, Kang AK, Zimpelmann J, Kennedy C et al. The effect of oral contraceptives on the nitric oxide system and renal function. Am J Physiol Renal Physiol 2007; 293 : F1539-F1544.
60. Meendering JR, Torgrimson BN, Miller NP, Kaplan PF, Minson CT. Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. Am J Physiol Heart Circ Physiol 2008; 294: H1630-H1637.
61. Torgrimson BN, Meendering JR, Kaplan PF, Minson CT. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol. Am J Physiol Heart Circ Physiol 2007; 292 H2874-H2880.